Bone loss induced by cancer treatments in breast and prostate cancer patients
Castañeda, Santos (Universidad Autónoma de Madrid)
Casas, Ana (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia))
González-del-Alba, Aránzazu (Hospital Universitario Puerta de Hierro Majadahonda (Madrid))
Martínez-Díaz-Guerra, Guillermo (Universidad Complutense de Madrid)
Nogués Solán, Xavier (Institut Hospital del Mar d'Investigacions Mèdiques)
Ojeda-Thies, Cristina (Hospital 12 de Octubre (Madrid))
Torregrosa, Oscar (Hospital General Universitario de Elche)
Rodríguez-Lescure, Álvaro (Hospital General Universitario de Elche)
Universitat Autònoma de Barcelona

Data:	2022
Resum:	Cancer and cancer therapies are a major factor risk for osteoporosis due to bone loss and deterioration of bone microarchitecture. Both factors contribute to a decrease in bone strength and, consequently, increased bone fragility and risk of fracture. Cancer-associated bone loss is a multifactorial process, and optimal interdisciplinary management of skeletal health, accurate assessment of bone density, and early diagnosis are essential when making decisions aimed at reducing bone loss and fracture risk in patients who have received or are receiving treatment for cancer. In this document, a multidisciplinary group of experts collected the latest evidence on the pathophysiology of osteoporosis and its prevention, diagnosis, and treatment with the support of the Spanish scientific society SEOM. The aim was to provide an up-to-date and in-depth view of osteoporotic risk and its consequences, and to present a series of recommendations aimed at optimizing the management of bone health in the context of cancer.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Antiresorptive agents ; Bone health ; Bone turnover marker ; Cancer ; Diagnosis ; Fragility fracture ; Hormone deprivation therapy ; Hormone therapy ; Osteoporosis
Publicat a:	Clinical & translational oncology, Vol. 24 Núm. 11 (november 2022) , p. 2090-2106, ISSN 1699-3055

DOI: 10.1007/s12094-022-02872-1
PMID: 35779210

17 p, 1.3 MB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats